Su1895 Plasma Methylated Sept9 is a Screening Marker in Both Left- and Right-Sided Colon Cancer. Comparison to FOBT and CEA Results
Kinga Tóth, Béla Molnár, Jürgen K. Beck, Kerstin Buser, Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Zsolt Tulassay(Semmelweis University), Vera Schellerer, Henriette Golcher(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 0
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis
|The American Journal of Surgical Pathology|2005|411
The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS
|Deutsches Ärzteblatt international|2020|258
The MicroRNA Profile of Prostate Carcinoma Obtained by Deep Sequencing
|Molecular Cancer Research|2010|227